640 related articles for article (PubMed ID: 27486821)
21. Targeting atypical protein kinase C iota reduces viability in glioblastoma stem-like cells via a notch signaling mechanism.
Phillips E; Lang V; Bohlen J; Bethke F; Puccio L; Tichy D; Herold-Mende C; Hielscher T; Lichter P; Goidts V
Int J Cancer; 2016 Oct; 139(8):1776-87. PubMed ID: 27299852
[TBL] [Abstract][Full Text] [Related]
22. Resveratrol promotes proteasome-dependent degradation of Nanog via p53 activation and induces differentiation of glioma stem cells.
Sato A; Okada M; Shibuya K; Watanabe E; Seino S; Suzuki K; Narita Y; Shibui S; Kayama T; Kitanaka C
Stem Cell Res; 2013 Jul; 11(1):601-10. PubMed ID: 23651583
[TBL] [Abstract][Full Text] [Related]
23. Cytomegalovirus Immediate-Early Proteins Promote Stemness Properties in Glioblastoma.
Soroceanu L; Matlaf L; Khan S; Akhavan A; Singer E; Bezrookove V; Decker S; Ghanny S; Hadaczek P; Bengtsson H; Ohlfest J; Luciani-Torres MG; Harkins L; Perry A; Guo H; Soteropoulos P; Cobbs CS
Cancer Res; 2015 Aug; 75(15):3065-76. PubMed ID: 26239477
[TBL] [Abstract][Full Text] [Related]
24. A new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one, suppresses stemness in glioma stem-like cells.
Kim RK; Kim MJ; Yoon CH; Lim EJ; Yoo KC; Lee GH; Kim YH; Kim H; Jin YB; Lee YJ; Cho CG; Oh YS; Gye MC; Suh Y; Lee SJ
Mol Pharmacol; 2012 Sep; 82(3):400-7. PubMed ID: 22648970
[TBL] [Abstract][Full Text] [Related]
25. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence.
Auffinger B; Spencer D; Pytel P; Ahmed AU; Lesniak MS
Expert Rev Neurother; 2015; 15(7):741-52. PubMed ID: 26027432
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1.
Bier A; Giladi N; Kronfeld N; Lee HK; Cazacu S; Finniss S; Xiang C; Poisson L; deCarvalho AC; Slavin S; Jacoby E; Yalon M; Toren A; Mikkelsen T; Brodie C
Oncotarget; 2013 May; 4(5):665-76. PubMed ID: 23714687
[TBL] [Abstract][Full Text] [Related]
27. miR-504 modulates the stemness and mesenchymal transition of glioma stem cells and their interaction with microglia via delivery by extracellular vesicles.
Bier A; Hong X; Cazacu S; Goldstein H; Rand D; Xiang C; Jiang W; Ben-Asher HW; Attia M; Brodie A; She R; Poisson LM; Brodie C
Cell Death Dis; 2020 Oct; 11(10):899. PubMed ID: 33093452
[TBL] [Abstract][Full Text] [Related]
28. Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma.
Singer E; Judkins J; Salomonis N; Matlaf L; Soteropoulos P; McAllister S; Soroceanu L
Cell Death Dis; 2015 Jan; 6(1):e1601. PubMed ID: 25590811
[TBL] [Abstract][Full Text] [Related]
29. Engagement of cellular prion protein with the co-chaperone Hsp70/90 organizing protein regulates the proliferation of glioblastoma stem-like cells.
Iglesia RP; Prado MB; Cruz L; Martins VR; Santos TG; Lopes MH
Stem Cell Res Ther; 2017 Apr; 8(1):76. PubMed ID: 28412969
[TBL] [Abstract][Full Text] [Related]
30. A curcumin derivative hydrazinobenzoylcurcumin suppresses stem-like features of glioblastoma cells by targeting Ca
Shin HJ; Lee S; Jung HJ
J Cell Biochem; 2019 Apr; 120(4):6741-6752. PubMed ID: 30390339
[TBL] [Abstract][Full Text] [Related]
31. Cardamonin induces apoptosis by suppressing STAT3 signaling pathway in glioblastoma stem cells.
Wu N; Liu J; Zhao X; Yan Z; Jiang B; Wang L; Cao S; Shi D; Lin X
Tumour Biol; 2015 Dec; 36(12):9667-76. PubMed ID: 26150336
[TBL] [Abstract][Full Text] [Related]
32. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
33. BRM270, a Compound from Natural Plant Extracts, Inhibits Glioblastoma Stem Cell Properties and Glioblastoma Recurrence.
Jeon HY; Park CG; Ham SW; Choi SH; Lee SY; Kim JY; Seo S; Jin X; Kim JK; Eun K; Kim EJ; Kim H
J Med Food; 2017 Sep; 20(9):838-845. PubMed ID: 28792781
[TBL] [Abstract][Full Text] [Related]
34. Targeting of glioma stem-like cells with a parthenolide derivative ACT001 through inhibition of AEBP1/PI3K/AKT signaling.
Hou Y; Sun B; Liu W; Yu B; Shi Q; Luo F; Bai Y; Feng H
Theranostics; 2021; 11(2):555-566. PubMed ID: 33391492
[TBL] [Abstract][Full Text] [Related]
35. Reversing glioma malignancy: a new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme.
Bielecka-Wajdman AM; Lesiak M; Ludyga T; Sieroń A; Obuchowicz E
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1249-1256. PubMed ID: 28500556
[TBL] [Abstract][Full Text] [Related]
36. Identification of GSK3β inhibitor kenpaullone as a temozolomide enhancer against glioblastoma.
Kitabayashi T; Dong Y; Furuta T; Sabit H; Jiapaer S; Zhang J; Zhang G; Hayashi Y; Kobayashi M; Domoto T; Minamoto T; Hirao A; Nakada M
Sci Rep; 2019 Jul; 9(1):10049. PubMed ID: 31296906
[TBL] [Abstract][Full Text] [Related]
37. Pterostilbene suppressed irradiation-resistant glioma stem cells by modulating GRP78/miR-205 axis.
Huynh TT; Lin CM; Lee WH; Wu AT; Lin YK; Lin YF; Yeh CT; Wang LS
J Nutr Biochem; 2015 May; 26(5):466-75. PubMed ID: 25736407
[TBL] [Abstract][Full Text] [Related]
38. Etoposide loaded layered double hydroxide nanoparticles reversing chemoresistance and eradicating human glioma stem cells in vitro and in vivo.
Wang Z; Liang P; He X; Wu B; Liu Q; Xu Z; Wu H; Liu Z; Qian Y; Wang S; Zhu R
Nanoscale; 2018 Jul; 10(27):13106-13121. PubMed ID: 29961791
[TBL] [Abstract][Full Text] [Related]
39. FK506 Attenuates the MRP1-Mediated Chemoresistant Phenotype in Glioblastoma Stem-Like Cells.
Torres Á; Arriagada V; Erices JI; Toro MLÁ; Rocha JD; Niechi I; Carrasco C; Oyarzún C; Quezada C
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30208561
[TBL] [Abstract][Full Text] [Related]
40. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
